Efficacy of olaparib monotherapy in patients (pts) with HER2-negative metastatic breast cancer (MBC) with germline BRCA mutation (gBRCAm) or lesional BRCA mutation (lBRCAm).

被引：0
|
作者：
Meisner, Eleanor
Rollins, Rebecca
Ensor, Joe
Moran, Amber
Woodward, Amanda
Ahn, Eugene R.
Lynch, Cynthia Anne
Citrin, Dennis L.
Hansra, Damien
Aithal, Sramila S.
Ninan, Mary
Nixon, Daniel W.
Zook, Susan
Ali, Siraj Mahamed
Markman, Maurie
Alvarez, Ricardo H.
机构：
[1] Univ Illinois, Rockford, IL USA
[2] Canc Treatment Ctr Amer, Newnan, GA USA
[3] Houston Methodist Canc Ctr, Houston, TX USA
[4] Sylvester Comprehens Canc Ctr, Miami Beach, FL USA
[5] VA Med Ctr, Jackson, MS USA
[6] Canc Treatment Ctr Amer, Zion, IL USA
[7] Canc Treatment Ctr Amer, Mt Laurel, NJ USA
[8] Univ Texas Med Branch, Friendswood, TX USA
[9] Morehouse Sch Med, Atlanta, GA 30310 USA
[10] Canc Treatment Ctr Amer, Boca Raton, FL USA
[11] Fdn Med Inc, Cambridge, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.1074
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1074
引用
收藏
页数：1
相关论文
共 50 条
  • [1] OlympiAD: Phase III trial of olaparib monotherapy versus chemotherapy for patients (pts) with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm).
    Robson, Mark E.
    Im, Seock-Ah
    Senkus, Elzbieta
    Xu, Binghe
    Domchek, Susan M.
    Masuda, Norikazu
    Delaloge, Suzette
    Li, Wei
    Tung, Nadine M.
    Armstrong, Anne
    Wu, Wenting
    Goessl, Carsten Dietrich
    Runswick, Sarah
    Conte, Pier Franco
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (18)
  • [2] OlympiAD: Phase III trial of olaparib monotherapy versus chemotherapy for patients (pts) with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm)
    Robson, Mark E.
    Im, Seock-Ah
    Senkus, Elzbieta
    Xu, Binghe
    Domchek, Susan M.
    Masuda, Norikazu
    Delaloge, Suzette
    Li, Wei
    Tung, Nadine M.
    Armstrong, Anne
    Wu, Wenting
    Goessl, Carsten Dietrich
    Runswick, Sarah
    Conte, Pier Franco
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [3] Tolerability of olaparib monotherapy versus chemotherapy in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: OlympiAD
    Domchek, Susan M.
    Robson, Mark
    Im, Seock-Ah
    Senkus, Elzbieta
    Xu, Binghe
    Masuda, Norikazu
    Delaloge, Suzette
    Li, Wei
    Armstrong, Anne
    Conte, Pierfranco
    Bannister, Wendy
    Goessl, Carsten
    Runswick, Sarah
    Goel, Saurabh
    Tung, Nadine
    CANCER RESEARCH, 2018, 78 (04)
  • [4] Subgroup analysis of olaparib monotherapy versus chemotherapy by hormone receptor and BRCA mutation status in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: OlympiAD
    Senkus-Konefka, E.
    Domchek, S. M.
    Im, S. A.
    Xu, B.
    Armstrong, A.
    Masuda, N.
    Delaloge, S.
    Li, W.
    Tung, N.
    Conte, P.
    Wu, W.
    Goessl, C.
    Runswick, S.
    Robson, M.
    EUROPEAN JOURNAL OF CANCER, 2018, 92 : S19 - S20
  • [5] Olaparib monotherapy for Asian patients with a germline BRCA mutation and HER2-negative metastatic breast cancer: OlympiAD randomized trial subgroup analysis
    Im, Seock-Ah
    Xu, Binghe
    Li, Wei
    Robson, Mark
    Ouyang, Quchang
    Yeh, Dah-Cherng
    Iwata, Hiroji
    Park, Yeon Hee
    Sohn, Joo Hyuk
    Tseng, Ling-Ming
    Goessl, Carsten
    Wu, Wenting
    Masuda, Norikazu
    SCIENTIFIC REPORTS, 2020, 10 (01)
  • [6] Olaparib monotherapy for Asian patients with a germline BRCA mutation and HER2-negative metastatic breast cancer: OlympiAD randomized trial subgroup analysis
    Seock-Ah Im
    Binghe Xu
    Wei Li
    Mark Robson
    Quchang Ouyang
    Dah-Cherng Yeh
    Hiroji Iwata
    Yeon Hee Park
    Joo Hyuk Sohn
    Ling-Ming Tseng
    Carsten Goessl
    Wenting Wu
    Norikazu Masuda
    Scientific Reports, 10
  • [7] OlympiAD final overall survival: Olaparib versus chemotherapy treatment of physician's choice (TPC) in patients with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm)
    Robson, Mark E.
    Im, Seock-Ah
    Senkus, Elzbieta
    Xu, Binghe
    Domchek, Susan
    Masuda, Norikazu
    Delaloge, Suzette
    Li, Wei
    Tung, Nadine
    Armstrong, Anne
    Wu, Wenting
    Goessl, Carsten
    Runswick, Sarah
    Conte, Pierfranco
    CANCER RESEARCH, 2018, 78 (13)
  • [8] Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
    Robson, Mark
    Im, Seock-Ah
    Senkus, Elzbieta
    Xu, Binghe
    Domchek, Susan M.
    Masuda, Norikazu
    Delaloge, Suzette
    Li, Wei
    Tung, Nadine
    Armstrong, Anne
    Wu, Wenting
    Goessl, Carsten
    Runswick, Sarah
    Conte, Pierfranco
    NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (06): : 523 - 533
  • [9] Olaparib monotherapy versus chemotherapy for patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: Asian subgroup analysis from the phase III OlympiAD trial
    Im, Seock-Ah
    Xu, Binghe
    Li, Wei
    Robson, Mark
    Ouyang, Quchang
    Yeh, Dah-Cherng
    Iwata, Hiroji
    Park, Yeon-Hee
    Sohn, Joo Hyuk
    Tseng, Ling-Min
    Goessl, Carsten
    Wu, Wenting
    Runswick, Sarah
    Masuda, Norikazu
    CANCER RESEARCH, 2018, 78 (04)
  • [10] Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer (OlympiAD): Efficacy in patients with visceral metastases
    Tung, Nadine M.
    Im, Seock-Ah
    Senkus-Konefka, Elzbieta
    Xu, Binghe
    Domchek, Susan M.
    Masuda, Norikazu
    Li, Wei
    Armstrong, Anne Caroline
    Conte, Pier Franco
    Wu, Wenting
    Goessl, Carsten Dietrich
    Runswick, Sarah
    Robson, Mark E.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
12345